

Oncology Molecular Diagnostics Market 2026-2030: Unveiling Growth Developments with the Latest Updates

The Business Research Company's Oncology Molecular Diagnostics Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, April 23, 2026

/EINPresswire.com/ -- "[Oncology Molecular Diagnostics market](#) to


surpass \$9 billion in 2030. Within the broader Medical Equipment industry, which is expected to be \$1,218 billion by 2030, the Oncology Molecular Diagnostics market is estimated to account for nearly 0.1% of the total market value.

Which Will Be The Biggest Region In The Oncology Molecular Diagnostics Market In 2030?

North America will be the largest region in the oncology molecular diagnostics market in 2030, valued at \$3.8 billion. The market is expected to grow from \$2.4 billion in 2025 at a compound annual growth rate (CAGR) of 10%. The strong growth can be


attributed to early commercialization of liquid biopsy technologies, strong adoption of companion diagnostics linked to targeted therapies, advanced bioinformatics infrastructure for genomic data analysis, high clinical trial activity in oncology, and strong integration of diagnostics with pharmaceutical pipelines across the USA and Canada.

Which Will Be The Largest Country In The [Global Oncology Molecular Diagnostics Market](#) In



2030?

The USA will be the largest country in the oncology molecular diagnostics market in 2030, valued at \$3.5 billion. The market is expected to grow from \$2.2 billion in 2025 at a compound annual growth rate (CAGR) of 10%. The strong growth can be attributed to strong ecosystem of diagnostic-pharma partnerships, increasing use of molecular diagnostics in treatment selection and therapy monitoring, high adoption of advanced genomic profiling platforms, rapid expansion of clinical oncology trials, and growing use of real-world data to support biomarker-driven therapies.



Request A Free Sample Of The Oncology Molecular Diagnostics Market Report

https://www.thebusinessresearchcompany.com/sample_request?id=3457&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR

What Will Be The Largest Segment In The Oncology Molecular Diagnostics Market In 2030?

The oncology molecular diagnostics market is segmented by product into instruments, reagents, and other products. The reagents market will be the largest segment of the oncology molecular diagnostics market, segmented by product, accounting for 58% or \$5 billion of the total in 2030. The reagents market will be supported by recurring demand from high-volume testing workflows, increasing use of assay kits for specific biomarker detection, growing need for standardized and validated test components, expansion of multiplex testing panels, rising adoption of liquid biopsy reagents, and continuous innovation in high-sensitivity assay chemistries.

The oncology molecular diagnostics market is segmented by technology into polymerase chain reaction (PCR), in-situ hybridization (ISH), isothermic nucleic acid amplification technology (INNAT), chips and microarrays, sequencing, mass spectroscopy, transcription mediated amplification (TMA), and other technologies. The polymerase chain reaction (PCR) market will be the largest segment of the oncology molecular diagnostics market, segmented by technology, accounting for 31% or \$3 billion of the total in 2030. The polymerase chain reaction (PCR) market will be supported by strong suitability for targeted mutation detection, widespread availability in clinical laboratories, rapid turnaround time for diagnostic results, increasing use in minimal residual disease (MRD) monitoring, advancements in digital PCR improving quantification accuracy, and cost-effectiveness for routine oncology testing.

The oncology molecular diagnostics market is segmented by end user into hospitals, diagnostic

centers, academic and research institutes, and other end users. The hospitals market will be the largest segment of the oncology molecular diagnostics market segmented by workflow, accounting for 39% or \$4 billion of the total in 2030. The hospitals market will be supported by increasing integration of in-house molecular diagnostic labs, rising demand for rapid diagnostic decision-making at point of care, growing adoption of multidisciplinary cancer treatment approaches, expansion of oncology departments within hospitals, increasing use of diagnostics in therapy monitoring, and need for seamless integration with clinical workflows and electronic health records.

What Is The Expected CAGR For The Oncology Molecular Diagnostics Market Leading Up To 2030?

The expected CAGR for the oncology molecular diagnostics market leading up to 2030 is 10%.

What Will Be The Growth Driving Factors In The Global Oncology Molecular Diagnostics Market In The Forecast Period?

The rapid growth of the global oncology molecular diagnostics market leading up to 2030 will be driven by the following key factors that are expected to reshape cancer detection methodologies, laboratory infrastructure standards, clinical decision-making frameworks, and innovation across global biomedical and healthcare ecosystems.

Increasing Prevalence Of Cancer And Early Detection Initiatives - The increasing prevalence of cancer and early detection initiatives is expected to become a key growth driver for the oncology molecular diagnostics market by 2030. The rising global incidence of cancer is driving the demand for advanced molecular diagnostic solutions in oncology. Early and accurate detection of genetic mutations, biomarkers, and tumor profiles allows for timely intervention, personalized treatment planning, and improved patient survival rates. Government health programs, cancer awareness campaigns, and routine screening initiatives are encouraging the adoption of molecular diagnostics in hospitals, clinics, and diagnostic laboratories. The increasing focus on precision oncology and early detection remains a key driver for market growth. As a result, the increasing prevalence of cancer and early detection initiatives is anticipated to contribute to 3.0% annual growth in the market.

Advancements In Genomic And Molecular Testing Technologies - The advancements in genomic and molecular testing technologies are expected to emerge as a major factor driving the expansion of the oncology molecular diagnostics market by 2030. Innovations such as next-generation sequencing (NGS), polymerase chain reaction (PCR)-based assays, liquid biopsies, and companion diagnostics are transforming oncology molecular diagnostics. These technologies enable high-throughput, sensitive, and specific detection of cancer-related genetic alterations, facilitating personalized medicine approaches. Integration of bioinformatics tools and AI-driven analytics further enhances the interpretation of complex molecular data, supporting targeted therapies and clinical decision-making. The rapid evolution of molecular testing technologies is a significant driver fueling market adoption globally. Consequently, the advancements in genomic and molecular testing technologies are projected to contribute to around 2.5% annual growth in

the market.

Rising Adoption Of Personalized And Targeted Cancer Therapies - The rising adoption of personalized and targeted cancer therapies is expected to act as a key growth catalyst for the oncology molecular diagnostics market by 2030. The shift towards precision oncology has created a growing need for molecular diagnostics to identify actionable mutations and guide targeted therapies. Oncology molecular diagnostics help physicians select appropriate treatment regimens, monitor therapy effectiveness, and adjust interventions based on patient-specific genetic profiles. As personalized medicine gains momentum, hospitals, research centers, and biotech companies are increasingly investing in molecular diagnostic tools, making this trend a strong driver for market growth. Therefore, the rising adoption of personalized and targeted cancer therapies is projected to contribute to approximately 1.5% annual growth in the market.

Access The Detailed Oncology Molecular Diagnostics Market Report Here

https://www.thebusinessresearchcompany.com/report/oncology-molecular-diagnostics-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR

What Are The Key Growth Opportunities In The Oncology Molecular Diagnostics Market in 2030?

The most significant growth opportunities are anticipated in the instruments market, the reagents market, and the other products market. Collectively, these segments are projected to contribute over \$3.4 billion in market value by 2030, driven by increasing adoption of multi-gene testing panels, rising demand for decentralized and rapid diagnostic solutions, expansion of precision oncology programs, growing integration of diagnostics with therapeutic development, and continuous advancements in high-throughput and automated testing platforms. This surge reflects the transition toward data-driven and patient-specific oncology care, enabling more accurate diagnosis, treatment selection, and disease monitoring.

The instruments market is projected to grow by \$1 billion, the reagents market by \$2 billion, and the other products market by \$0.4 billion over the next five years, from 2025 to 2030.

Learn More About [The Business Research Company](#)

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business

Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:

The Business Research Company

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email: info@tbrc.info

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/907508585>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.